Table 2.
Characteristics of Total Solid Organ Transplant Recipients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
| No. | % | |
|---|---|---|
| Location | ||
| United States | 249 | 57.51% |
| Italy | 55 | 12.7% |
| China | 26 | 6% |
| Organ transplanted | ||
| Kidney | 252 | 58.2% |
| Liver | 89 | 20.6% |
| Heart | 51 | 11.8% |
| Other organ∗ | 42 | 9.6% |
| Sex | ||
| Male | 264 | 61.0% |
| Comorbidity | ||
| HTN | 249 | 57.5% |
| DM | 159 | 36.7% |
| Obesity | 44 | 10.2% |
| CKD | 77 | 17.8% |
| Immunosuppressive | ||
| Tac | 160 | 37.0% |
| CNI | 122 | 28.2% |
| Prednisone or other steroid | 217 | 50.1% |
| MMF/MPA | 214 | 49.4% |
| Other immunosuppressive† | 125 | 28.8% |
Abbreviations: CKD, chronic kidney disease; CNI, calcineurin inhibitor; DM, diabetes mellitus; HTN, hypertension; MMF, mycophenolate mofetil; MPA, mycophenolic acid; Tac, tacrolimus.
∗
Includes lung, pancreas, and multiple solid organ transplant.
†
Includes mammalian target of rapamycin, belatacept, leflunomide, mizoribine, cyclosporine, azathioprine, intravenous immunoglobulin/pheresis, basiliximab, T-cell–depleting agents, CNI + MMF, and triple therapy.